Conglomerate GE and biotech firm Bionime this morning announced that they signed a worldwide licensing agreement to manufacture and distribute medical technology for diabetics.
The first product that will surface from the deal is the GE100 Blood Glucose Monitoring System, which will appear on retail shelves in 2012. (It’s available now for medical suppliers.) GE says it’s more accurate and sanitary than comparable glucometers.
True Auto Coding
Testing made simple. Reduce false test results due to coding errors with the one-of-a-kind True Auto Coding feature.
Accurate
Noble Metal Electrodes and a patented strip structure provides highly accurate and reliable results in about 5 seconds.
Large Screen
Know your results in a glance with the easy to read, extra large display.
Clean & No Mess
Innovative application port, grip handle and top loading feature reduce unnecessary sample handling for a cleaner testing experience.
Easy to Handle
Easy to hold, use and test. Palm-sized meter and big buttons combined with extra large, plastic reinforced test strips make handling easier than ever.
Tiny Blood Sample
The GE100 requires only a small amount of blood for accurate results.
The deal is an important one: there are more than 346 million diabetics around the globe, and Type 2 diabetes is the fastest growing chronic disease worldwide.
The Bionime deal instantly provides GE’s Healthcare division with glucose monitors, test strips, kits and accessories to market; accordingly, the deal also gives Bionime tremendous scale in terms of distribution channels and a trusted name to leverage.
